Standard BioTools Inc. Gain (Loss) on Extinguishment of Debt
Standard BioTools Inc. (LAB) reported Gain (Loss) on Extinguishment of Debt of -$9.00 thousand for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-08.
Discontinued › Expense Statement › Operating Expenses
us-gaap:GainsLossesOnExtinguishmentOfDebt · last filed 2022-03-08
- Standard BioTools Inc. gain (loss) on extinguishment of debt for the quarter ending 2020-12-31 was $0.00.
- Standard BioTools Inc. gain (loss) on extinguishment of debt for the quarter ending 2020-09-30 was $0.00.
- Standard BioTools Inc. gain (loss) on extinguishment of debt for the quarter ending 2020-06-30 was $0.00.
- Standard BioTools Inc. gain (loss) on extinguishment of debt for the quarter ending 2020-03-31 was $0.00.
- Standard BioTools Inc. gain (loss) on extinguishment of debt for fiscal 2021 was -$9.00K.
- Standard BioTools Inc. gain (loss) on extinguishment of debt for fiscal 2020 was $0.00.
- Standard BioTools Inc. gain (loss) on extinguishment of debt for fiscal 2019 was -$12.02M.
- Standard BioTools Inc. gain (loss) on extinguishment of debt for fiscal 2018 was $0.00.
| Period end | Gain (Loss) on Extinguishment of Debt 3 month | Gain (Loss) on Extinguishment of Debt 6 month | Gain (Loss) on Extinguishment of Debt 9 month | Gain (Loss) on Extinguishment of Debt 12 month |
|---|---|---|---|---|
| 2021-12-31 | -$9.00K 10-K · filed 2022-03-08 | |||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-08 | $0.00 derived: sum of 2 quarters · filed 2022-03-08 | $0.00 derived: sum of 3 quarters · filed 2022-03-08 | $0.00 10-K · filed 2022-03-08 |
| 2020-09-30 | $0.00 10-Q · filed 2020-11-09 | $0.00 derived: sum of 2 quarters · filed 2020-11-09 | $0.00 10-Q · filed 2020-11-09 | -$3.02M derived: sum of 4 quarters · filed 2022-03-08 |
| 2020-06-30 | $0.00 10-Q · filed 2020-08-07 | $0.00 10-Q · filed 2020-08-07 | -$3.02M derived: sum of 3 quarters · filed 2022-03-08 | -$3.02M derived: sum of 4 quarters · filed 2022-03-08 |
| 2020-03-31 | $0.00 10-Q · filed 2020-05-11 | -$3.02M derived: sum of 2 quarters · filed 2022-03-08 | -$3.02M derived: sum of 3 quarters · filed 2022-03-08 | -$3.02M derived: sum of 4 quarters · filed 2022-03-08 |
| 2019-12-31 | -$3.02M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-08 | -$3.02M derived: sum of 2 quarters · filed 2022-03-08 | -$3.02M derived: sum of 3 quarters · filed 2022-03-08 | -$12.02M 10-K · filed 2022-03-08 |
| 2019-09-30 | $0.00 10-Q · filed 2020-11-09 | $0.00 derived: sum of 2 quarters · filed 2020-11-09 | -$9.00M 10-Q · filed 2020-11-09 | -$9.00M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | $0.00 10-Q · filed 2020-08-07 | -$9.00M 10-Q · filed 2020-08-07 | -$9.00M derived: sum of 3 quarters · filed 2021-02-25 | -$9.00M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-03-31 | -$9.00M 10-Q · filed 2020-05-11 | -$9.00M derived: sum of 2 quarters · filed 2021-02-25 | -$9.00M derived: sum of 3 quarters · filed 2021-02-25 | -$9.00M derived: sum of 4 quarters · filed 2021-02-25 |
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $0.00 derived: sum of 2 quarters · filed 2021-02-25 | $0.00 derived: sum of 3 quarters · filed 2021-02-25 | $0.00 10-K · filed 2021-02-25 |
| 2018-09-30 | $0.00 10-Q · filed 2019-11-08 | $0.00 derived: sum of 2 quarters · filed 2019-11-08 | $0.00 10-Q · filed 2019-11-08 | |
| 2018-06-30 | $0.00 10-Q · filed 2019-08-07 | $0.00 10-Q · filed 2019-08-07 | ||
| 2018-03-31 | $0.00 10-Q · filed 2019-05-07 | |||
| 2017-12-31 | $0.00 10-K · filed 2020-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |